December 21, 2015—Healthcare providers that can't obtain 340B pricing on a covered outpatient drug and can't get satisfaction from their wholesaler and/or the drug manufacturer shouldn't hesitate to bring the problem to the government's attention, federal officials say. … [Read more...]
Prices for Many Generic Drugs Outpacing Inflation Benchmark
Medicaid rebates would be $1.4 billion greater if inflation penalty had been in placeDecember 17, 2015—Medicaid would have received an additional $1.4 billion in rebates on the top 200 generic drugs for 2005 through 2014 if the rebate calculation for generic drugs contained an inflationary adjustment similar to the one applicable to brand-name drugs, the Department of Health and Human Services Office of Inspector General says in a new report. … [Read more...]
Safety-Net Healthcare Coalition Launches 340B Website
340BCoalition.org explains, extols, and defends drug discount programDecember 17, 2015—The 340B Coalition, a national group of safety-net healthcare providers in the 340B drug discount program, has launched 340BCoalition.org, a website that explains, extols, and defends the program. … [Read more...]
Spending Bill Would Level-Fund 340B Program
Appropriators request HRSA briefing on mega-guidance, secure website, and covered entitiesDecember 16, 2015—The House and Senate have agreed on legislation to fund the federal government through the end of the fiscal year that would keep the 340B drug discount program level-funded at $10.24 million. … [Read more...]
Feds Won’t Appeal 340B Orphan Drug Exclusion Ruling
HRSA is evaluating next stepsDecember 15, 2015—The federal government will not appeal the Oct. 14 federal district court decision that vacated the Department of Health and Human Services' 340B orphan drug exclusion interpretive rule. … [Read more...]
OMB Clears Long-Awaited Medicaid Drug Pricing Rule
CMS published regulation for comment nearly four years agoDecember 15, 2015—The White House Office of Management and Budget has finished reviewing the so-called Medicaid average manufacturer price (AMP) final rule, potentially clearing the way for its publication before the end of the year. … [Read more...]
MedPAC Considers Draft Recommendation to Cut 340B Hospitals’ Medicare Drug Reimbursement
Savings would go to Medicare's hospital uncompensated care payment poolDecember 11, 2015—Congress should reduce Medicare Part B drug reimbursement for 340B hospitals by 10 percent of a drug's average sales price (ASP) and redistribute the estimated $300 million in savings to hospitals providing the most uncompensated care through Medicare's hospital uncompensated care payment pool, the chairman of the Medicare Payment Advisory Commission proposed … [Read more...]